Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets …
Full GRFS analysis →
Competitive advantage assessment
Key strengths
Margins Stable Across CyclesOperating margin volatility is low (stability score 0.89), demonstrating pricing resilience across cycles.
Operating Leverage in EffectOperating leverage is evident (score 0.83), with margins expanding over time.
Key risks
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.39), suggesting weak customer stickiness.
Grifols, S.A. ranks #12 of 20
scored companies in Drug Manufacturers - General by moat score — the top 60%.
The widest moat in the group is Novo Nordisk A/S (NVO)
at 74/100.
Moat scores for companies ranked near GRFS in Drug Manufacturers - General
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 67
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 31
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 50
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 42
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 53
· 15% of the moat score
Scale matters only when it converts into economics.
Grifols, S.A. (GRFS) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #12 of 20 scored companies in Drug Manufacturers - General, the top 60%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Cost Advantage (67/100) and its weakest is Customer Stickiness (31/100).
How does Grifols, S.A. compare with other Drug Manufacturers - General companies?
Grifols, S.A. ranks #12 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are GSK plc (GSK) at 52 just above it and Eli Lilly and Company (LLY) at 45 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is Grifols, S.A. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Grifols, S.A.?
The Corporate Default template measures 6 defenses, and GRFS scores: Pricing Power (56), Cost Advantage (67), Customer Stickiness (31), Capital Efficiency (50), Resilience (42), Scale & Market Position (53). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.